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A plasma component is responsible for altered glomerular permeability in patients with focal segmental glomerulosclerosis.
Evidence includes recurrence after renal transplantation, remission after plasmapheresis, proteinuria in infants of affected mothers,
transfer of proteinuria to experimental animals, and impaired glomerular permeability after exposure to patient plasma. Therapy
may include decreasing synthesis of the injurious agent, removing or blocking its interaction with cells, or blocking signaling or
enhancing cell defenses to restore the permeability barrier and prevent progression. Agents that may prevent the synthesis of
the permeability factor include cytotoxic agents or aggressive chemotherapy. Extracorporeal therapies include plasmapheresis,
immunoadsorption with protein A or anti-immunoglobulin, or lipopheresis. Oral or intravenous galactose also decreases 𝑃alb
activity. Studies of glomeruli have shown that several strategies prevent the action of FSGS sera. These include blocking receptorligand interactions, modulating cell reactions using indomethacin or eicosanoids 20-HETE or 8,9-EET, and enhancing cytoskeleton
and protein interactions using calcineurin inhibitors, glucocorticoids, or rituximab. We have identified cardiotrophin-like cytokine
factor 1 (CLCF-1) as a candidate for the permeability factor. Therapies specific to CLCF-1 include potential use of cytokine receptorlike factor (CRLF-1) and inhibition of Janus kinase 2. Combined therapy using multiple modalities offers therapy to reverse
proteinuria and prevent scarring.

1. Introduction
Nephrotic syndrome is defined by loss of protein in the
urine, decreased plasma albumin, fluid retention resulting in
edema formation, and, in many cases, hyperlipidemia. The
discovery of mutations in nephrin as the genetic cause of
proteinuria that characterizes Finnish nephropathy [1] led
to the understanding that nephrotic syndrome is the result
of glomerular podocyte dysfunction. Persistent proteinuria
is a precursor of renal scarring and decline in glomerular
filtration and may, indeed, be a cause of progression of
renal disease. Mutations affecting the structure or function of
podocytes or their response to injury may lead to proteinuria
and to glomerular scarring. However, currently identified
monogenic disorders account for a minority of cases [2], and

the cause of podocyte dysfunction or loss leading to nephrotic
syndrome is not known in most patients. Glomerular scarring
may affect only certain segments of a minority of glomeruli
in a pattern termed focal and segmental glomerulosclerosis
(FSGS). FSGS is an orphan disease representing a syndrome
with many causes [3] and is the cause of about 3.3% of endstage-renal disease in the United States [4]; it occurs worldwide and affects all races and ethnic groups. The frequency
of FSGS appears to be increasing worldwide [5]. Certain
patients with renal failure due to FSGS experience recurrence
of proteinuria and of progressive renal dysfunction after renal
transplantation [6]. This review will focus on the rationale
for therapies and on trials that address mechanisms that
may reverse proteinuria and prevent or delay renal failure in
patients with nephrotic syndrome and features of FSGS. Such
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therapies may be useful in treatment of idiopathic nephrotic
syndrome (INS) and in the treatment of recurrent FSGS in
renal allografts.

2. Mutations That Point to
Therapeutic Targets
Analysis of the mutated proteins in familial or monogenetic
FSGS indicates several podocyte functions that render them
vulnerable to injury or loss. Some are structural podocyte
proteins including those of the slit-diaphragm (nephrin,
Neph1), actin associated proteins (alpha-actinin 4) [11],
CD2AP [12], and podocin [13]. Others are components of
the glomerular basement membrane (GBM) [14, 15] and of
the attachment complex including integrins [16] that provide
physical adherence as well as “outside-in” signaling that
maintain differentiated function. Still others are channels
such as TRPC6, a gated calcium channel [17], mutations
of which may predispose to injury mediated by increased
magnitude and duration of signals by ANG II and other
humoral responses. Finally, mitochondrial disorders lead
to impaired energy availability and cellular damage [18].
APOL 1 risk mutations lead to increased incidence and rapid
progression of FSGS in certain African Americans [19]. Each
of these mutations leads to potential for therapies to protect
or stabilize podocyte function and to minimize injury to the
filtration barrier and consequent glomerulosclerosis. Current
technology permits testing for these and other mutations
[20]. The study of a cohort of patients with nephrotic
syndrome is ongoing [21] and new point mutations associated
with FSGS continue to be identified from whole genome
sequencing [2].

3. Clinical and Experimental Evidence for a
Circulating Factor
Evidence for the presence of a circulating factor that causes
glomerular or podocyte injury and proteinuria includes early
onset of proteinuria after renal transplantation in patients
with FSGS [22], occurrence of proteinuria in infants of
mothers with FSGS [23], transmission of proteinuria to rats or
mice by FSGS plasma or fractions thereof [24, 25], remission
after plasmapheresis [26, 27] or immunoadsorption with
protein A [28] or anti-human IG [29] columns, and recovery
of proteinuria in a transplanted kidney after retransplantation
into a patient without FSGS as his underlying disease [30]. NS
in each of these settings is initiated and perpetuated by factor
or factors that are extrinsic to the kidney but intrinsic to blood
that is perfusing the kidney. The identity of this substance has
not been proven.

4. Role of Lymphocytes in NS
Lymphocytes have been implicated in the etiology of
INS/FSGS on the basis of clinical observations and response
to therapy and several experimental models in mice and rats.
The initial postulate that T lymphocytes are the source of
a substance causing proteinuria in INS was put forward by
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Shalhoub in 1974 [31]. This theory had no experimental basis
but was derived from clinical observations including the lack
of evidence of a humoral antibody response and remission
induced by measles, steroids, or cyclophosphamide. The
observations that lymphoma was sometimes accompanied
by NS and that therapy resolved proteinuria reinforced
the potential causal relationship. Studies of lymphocytederived products have failed to identify any unique etiological
substance in INS. Glucocorticoids remain in use as firstline agents in INS and the severity of renal disease in INS
is often defined by the responsiveness to corticosteroids.
Steroid resistant or steroid dependent INS is more likely to
progress to pathological FSGS and to renal failure than is
steroid sensitive INS. ACTH, first introduced in the 1950s,
has returned as ACTH gel (H.P. Acthar Gel, Mallinckrodt
Pharmaceutical) [32, 33] It appears to have efficacy that may
exceed that of glucocorticoids, perhaps because of interaction
of the melanocortin receptor, MC1R [33–35]. B cells have
also been implicated by the efficacy in some human trials of
rituximab or similar monoclonal antibodies that target CD40
on B cells and podocytes
A model of FSGS in which glomerular damage appears to
be mediated by abnormal T cells is that of the Buffalo/Mna
rat. Rats develop proteinuria by 8 weeks of age. There is
accompanying macrophage activation and expression of Th2
lymphocyte markers. Kidneys transplanted into affected rats
develop glomerular injury. Investigators postulated that a
circulating proteinuric substance might be present in both
native and transplanted kidneys but have not identified
this substance [36, 37]. An additional model of MCNS was
derived by injecting CD34(+) stem cells or CD34(−) peripheral blood mononuclear cells from afflicted patients into
immunocompromised mice. Both CD34(+) and CD34(−)
cells lead to engraftment of human CD45(+) leukocytes but
only CD34(+) cells induced albuminuria. Glomeruli from
proteinuric mice showed podocyte foot process effacement.
Authors concluded that cells responsible for INS are likely
to be immature differentiating cells rather than mature
peripheral T cells [38]. No follow-up studies using this model
have been published.
Participation of B cells in FSGS is suggested by the success
of anti-B cell antibodies such as Rituximab in FSGS therapy
as well as by clinical responses to immunoadsorption using
protein A [39] or anti-human IgG [40]. Although there is
no antibody staining in FSGS or its recurrence, a survey of
sera from patients with recurrent FSGS contained a large
number of autoantibodies compared to non-FSGS patients
(7800 antibodies versus 780 in patients with other renal
diseases). Ten proteins were selected from those represented
in the kidney to make up a panel for testing as a marker
for recurrence of FSGS after transplantation [41]. Antibodies
included anti-CD40, PTPRO, CGB5, FAS, P2RY11, SNRPB2,
and APOL2. Positive results using this panel had a high predictive value of posttransplant recurrence in a retrospective
cohort of 64 transplanted FSGS patients. Anti-CD40 was the
most highly related to recurrent FSGS. Authors presented
evidence that suPAR and anti-CD40, given together in mice,
produced significant proteinuria and that blocking activation
of 𝛼v𝛽3 integrin interfered with this proteinuria. No further
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studies regarding this interaction have been published but its
relevance and the potential for future clinical trials has been
proposed in a recent review [42]. We have observed that a
monoclonal antibody to PTPRO increases 𝑃alb during in vitro
testing [43].
Bone marrow transplantation has been used to decrease
the incidence of recurrence after renal transplantation; the
optimal use of this strategy has not been established [44].
We have reported that 𝑃alb activity and proteinuria were
abolished for more than 10 years in a patient who was treated
with standard therapy for Hodgkin’s lymphoma [45]. This
case report illustrates the potential role of aggressive cytotoxic
therapy in eliminating circulating permeability factor or
factors.

5. Lessons from In Vitro Studies of Isolated
Glomeruli and Cultured Podocytes
Additional information about renal responses in FSGS has
been derived from studies of isolated glomeruli or of cultured
podocytes. We and others have incubated glomeruli from
experimental animals with plasma or sera from individuals
with INS or FSGS or with other noninflammatory renal diseases [8, 46, 47]. The original assay is based on measurement
of capillary expansion after filtration across the capillary wall
in response to an albumin oncotic gradient. Convectional
albumin permeability of the glomerular capillary barrier is
calculated from the increase in glomerular volume as shown
in Figure 1(a). Calculation is as follows [7]. Glomerular
volume in each condition is calculated from the geometric
mean of 4 diameters at 45∘ angles as indicated using the
formula: 𝑉 = (4/3)𝜋(𝑑/2)3 . Volume increase is calculated as
follows: Δ𝑉 = 𝑉1% − 𝑉5% . Since Δ𝑉 ∝ Δoncotic pressure ×
𝜎albumin , 𝜎albumin control = 1, 𝜎albumin experimental can be calculated as follows: Δ𝑉experimental /Δ𝑉control . We have defined
albumin permeability after experimental treatment from the
formula: 𝑃albumin experimental = (1 − 𝜎albumin experimental ) or (1 −
Δ𝑉experimental /Δ𝑉control ). 𝑃albumin or 𝑃alb is a dimensionless
parameter which ranges from zero in the normal glomerular
capillary to a maximum of 1.0 after injury.
We have used the assay to define an activity level,
termed “𝑃alb activity” or simply “𝑃alb ” [48]. We and our
colleagues have recently reported the use of a comparable
method in which fluorescent albumin is used as a marker
for filtration and for measuring 𝑃alb [49]. 𝑃alb testing has
been standardized using normal or patient plasma in a 1 : 50
dilution and an oncotic gradient of 16–20 mm Hg [8]. Sera of
children with INS cause moderate damage to the glomerular
protein filtration barrier [47] while sera of individuals with
collapsing FSGS [46] or from patients with posttransplant
recurrence of FSGS caused a profound loss of barrier function
[8]. The assay is reliable across a range of observers. The
correlation coefficient between values of replicate samples
from 35 patients was 0.72 (𝑝 < 0.001) [8] and have been
stable and reproducible in studies of human samples and the
original assay and its modifications have been employed in a
wide range of experimental protocols for more than 30 years
in several centers [49–51].
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Studies of the effects of plasma or serum from patients
with FSGS on isolated glomeruli have documented a profound and nearly immediate increase in 𝑃alb . The increase is
accompanied and is dependent on phosphorylation of JAK2
and STAT3 [9]. Comparable activation of the JAK/STAT
pathway occurs in cultured immortalized podocytes incubated with FSGS serum [9]. The effect of patient serum is
greatest in samples from patients with the most aggressive
renal disease as indicated both by a more rapid course
to ESRD [52] and by comparison of the very high 𝑃alb
activity of sera from patients with collapsing FSGS [46] or
recurrence after transplantation versus those with MCNS or
transplantation without recurrence [8]. 𝑃alb activity predicts
posttransplant recurrence in patients with podocin mutations
[53]. 𝑃alb activity is decreased or abolished by PP [8, 54] or
IA with protein A [40]. Activity is blocked by JAK or STAT
inhibitors [9], by the addition of galactose or adsorption
of sera on a galactose column [55], or by a variety of
potential therapeutic agents including indomethacin [56],
cyclosporine A [57], NO, acting as a superoxide scavenger
[58], antibody to CLCF-1 or by CRLF-1 [9], extract of
Tripterygium wilfordii [59], and eicosanoids 20-HETE [60]
and 8,9 EET [61]. One or more components from plasma of
humans and other mammals [62, 63] and urine from patients
with recurrent FSGS also block 𝑃alb activity [64].

6. Proposed Candidates for the FSGS
Permeability Factor
We and others have attempted to identify substance or
substances in the plasma of patients with FSGS, especially
those who are resistant to therapy or who progress to ESRD
and experience recurrent nephrotic syndrome and FSGS after
transplantation [25]. Historical candidates as proteinuric
factors include vascular permeability factor (VPF) that is
synthesized by T cells [65] and hemopexin [66]. More
recently, elevated concentrations of soluble urokinase-type
plasminogen activator receptor (suPAR) have been reported
in patients with FSGS. This finding and results of studies of
cultured podocytes have led to the proposal of suPAR as a
lead candidate as an etiological factor in FSGS. Studies of
cultured podocytes have been interpreted as supportive [67].
SuPAR effects include altered cytoskeleton in immortalized
podocytes, altered podocyte attachment with activation of
𝛽3 integrin [68], and activation of STAT1 in vascular smooth
muscle cells via a PDGFR receptor [69]. SuPAR has numerous
other effects on several cell types including alteration of
mobilization and migration and of mesenchymal stem cells
[70]. Other investigators have disputed the interpretation of
the experimental and clinical findings regarding suPAR [71,
72]. Active investigations are ongoing, but suPAR is elevated
in many inflammatory states and in diabetes mellitus. SuPAR
appears to be associated with progression of renal disease
regardless of its etiology [73, 74]. Circulating suPAR is
increased in renal failure in part because of diminished loss
in urine [75]. Understanding of the role that suPAR plays in
the initiation and progression of renal disease, including INS
and FSGS, is incomplete.
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(a) (i) Video micrograph of a glomerulus isolated from a normal rat. (ii) Cartoon of planar area
traced from micrograph in medium containing 5% BSA. Diameters used to calculate glomerular
volume are indicated as d1, d2, d3, and d4. (iii) Area after exposure to medium with 1% albumin
concentration. (iv) Difference between images in 5% and 1% BSA. Increase in glomerular size is
consequent to distension of glomerular capillaries. Calculations used to determine 𝑃albumin are
detailed in the text

Relation between P；Ｆ＜ and glomerular volume increase
% volume increase

10
8

Normal glomerulus
 = 1; P；Ｆ＜ = 0

6
4

Injured glomerulus
 = 0.2; P；Ｆ＜ = 0.8

2
0
0

4
6
Albumin oncotic gradient (mm Hg)

12

(b) An example of the increase in glomerular volume in an untreated
control glomerulus (solid line) and in a glomerulus after treatment
with an injurious agent such as protamine (dotted line) as described
previously [7, 8]. Here 𝑃alb of the injured glomerulus is about 0.8. The
figure has been redrawn from prior published figures

Figure 1

A role for lipoproteins in FSGS is suggested by reports
of successful therapy using lipopheresis and by the presence of abnormal lipids in proteomic analyses. In addition,
lipoproteins have been proposed both as inhibitors of FSGS

permeability activity and as candidates for the active factor.
Specific apolipoproteins that act as inhibitors of 𝑃alb activity
of FSGS sera include APO-E2, APO-E4, and fragments of
APO-A iv [76]. Genotyping of apolipoproteins did not reveal
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differences between FSGS patients who were sensitive to
steroids and those who were resistant to therapy [77]. In
contrast, a form of APO-A1 was identified in plasma only in
recurring FSGS patients and was absent from those without
recurrence [78]. Additional observations that implicate lipids
in proteinuria are derived from work indicating the role of
rituximab as an inhibitor of downregulation of podocyte
sphingomyelinase-like phosphodiesterase 3b (SMPDL-3b)
[79].
We have recently performed studies to enrich 𝑃alb activity
of recurrent FSGS plasma and have identified cardiotrophinlike cytokine-1 (CLCF-1) in the active fraction of FSGS plasma
using tandem LC-MS/MS [10, 80]. CLCF-1 is best known
for its action through the JAK/STAT pathway. CLCF-1 is a
member of the IL-6 family of cytokines. CLCF-1 was initially
cloned from T cells [81, 82] and is a neurotrophic and B cell
stimulating factor that increases expression of immunoglobulins. CLCF-1 acts through a complex receptor composed
of CNTFR, LIFR, and gp130 [83]. Gp130 defines the IL-6
family of cytokines while, in the case of CLCF-1, CNTFR
and LIFR confer specificity [84]. The IL-6 family includes
a number of pleiotropic cytokines which are expressed by
both bone marrow derived and somatic cells. The IL-6 family
includes erythropoietin, Leukemia Inhibitory Factor (LIF),
and Ciliary Neurotrophic Factor (CNTF), as well as IL-6
itself. CLCF-1 has 3 potential binding sites and we have shown
that activation of podocytes is prevented interaction with
CRLF-1 [9], a related and cosecreted cytokine [85]. Receptorligand binding initiates signaling by the JAK/STAT pathway.
We have reported that podocytes express primarily JAK2 and
STAT3 [10] and each is activated by tyrosine phosphorylation
by CLCF-1 at specific sites. STAT3 activation of peripheral
blood cells is immediate and returns to normal within 24
hours [10]. In contrast, STAT3 phosphorylation in the renal
cortex persists for at least 72 hours [10]. pSTAT3 is present in
glomeruli at a location consistent with podocytes as well as
in vascular smooth muscle within the kidney and proximal
tubule cells [10]. CLCF-1 also activates STAT3 in cultured
murine or human podocytes and simultaneously alters the
actin cytoskeleton [10]. These changes may be analogous to
those required for foot process retraction in vivo during
proteinuric states.
We have shown that 𝑃alb activity is removed by plasmapheresis (PP) with a kinetic pattern comparable to that of
immunoglobulins and that activity can be recovered from
discarded plasmapheresis fluid [8]. We have followed 𝑃alb
activity during sequential fractionation of FSGS plasma
obtained by plasmapheresis [25, 86]. The active component
of the plasma fraction is soluble in ammonium sulfate at a
concentration of 70% but precipitates at 80%. Injection of
this fraction into rats results in proteinuria [25]. In additional
studies, we found that 𝑃alb activity is retained on a column of
galactose-coated agarose beads and can be recovered by elution using a galactose solution [55]. Activity is retained by a
filtration membrane with molecular weight cut-off of 30 kDa.
We have performed liquid chromatography/tandem mass
spectrometry (LC/MS/MS) on the plasma fraction obtained
by galactose affinity chromatography of FSGS plasma and
have identified a candidate cytokine, cardiotrophin-like
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cytokine factor-1 (CLCF-1) [80]. This cytokine mimics the 𝑃alb
activity of FSGS plasma [9, 10] and a monoclonal antibody
to CLCF-1 markedly decreases the activity of FSGS sera
[9]. In addition, both FSGS serum and CLCF-1 activate the
JAK2/STAT3 pathway [9]. 𝑃alb activity of FSGS serum as
well as that of CLCF-1 is inhibited by specific inhibitors of
JAK2 and STAT3 [9] and by FDA approved JAK inhibitors
ruxolitinib (Incyte), by tofacitinib (Pfizer), and by baricitinib
(E. Lilly), which is in review by the FDA. 𝑃alb activity
and podocyte STAT phosphorylation are also inhibited by
cytokine receptor-like factor-1 (CRLF-1), a cytokine which
dimerizes with CLCF-1 [9]. The effects of CLCF-1 on 𝑃alb and
on JAK2 and STAT3 activation are shown in Figures 2(a)
and 2(b). Figure 2(c) illustrates that JAK2 inhibition blocks
the effect of FSGS sera on 𝑃alb activity of sera from FSGS
patients (Figure 2 depicts data previously published [9, 10]).
We are continuing to investigate the role of CLCF-1, CRLF-1,
and related molecules in the genesis of proteinuria in FSGS
in native kidneys and in posttransplant recurrence of FSGS
using isolated glomeruli, cultured podocytes, and responses
in intact rodents.
The question of design and interpretation of animal models for recurrent FSGS mediated by a circulating molecule or
molecules has not been resolved. Proteinuria is a multistep
process. The initial change in permeability is the result of
podocyte signaling and a functional increase in permeability.
Filtered albumin is reabsorbed by the proximal tubule and
reabsorption may delay recognition of the altered filtration
barrier. Visual confirmation of proximal tubule reabsorption
is provided by 2-photon imaging of rat kidneys in several
models of proteinuria [87]. Anatomical changes follow and
include impaired podocyte architecture and attachment and
to podocyte loss. Glomerular segmental scarring is evident
only in later phases and leads to altered hemodynamics
and rheology. It is proposed that loss of podocytes exposes
glomerular basement membrane and permits movement of
parietal epithelial cells to vacant basement membrane where
they form an attachment [88] that alters the geometry of both
the capillary and Bowman’s space. As the disease advances,
there is scarring in the tubular interstitial compartment with
capillary loss, tubular atrophy, and collagen accumulation.
Late in the process, local or circulating cells and soluble
substances alter the interstitium leading to accumulation of
extracellular material and interstitial fibrosis. The role of the
circulating permeability factor in each of these processes is
not known. In our opinion, many of the later events that
lead to progressive renal failure are shared with other renal
diseases.
We propose that models that are based on effects of
toxins such as puromycin, adriamycin, bisphosphonates, or
reduced nephron number [89] or on podocyte death induced
by diphtheria toxin in genetically modified mice [90] or by
antibodies to podocytes [91] are not suitable models for the
early and reversible proteinuria of recurrence FSGS after
transplantation. We have focused on the initiating steps of
podocyte signaling and altered attachment rather than on
processes that determine subsequent glomerular scarring and
interstitial fibrosis. We believe that this focus may permit the
design of preemptive treatment. To date, no animal model of
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(a) Effect of FSGS serum or CLCF-1 on 𝑃alb of glomeruli isolated
from normal rats. The increases by FSGS serum and CLCF-1 were
comparable in magnitude. Each was prevented by a monoclonal
antibody to CLCF-1, by the heterodimer CLCF-1/CRLF-1, or by the
specific JAK2 inhibitor, BMS91154. Data from Sharma et al. [9]
1

1

2

CLCF-1

(b) Western blots showing JAK2 and STAT3 phosphorylation in
cultured immortalized murine podocytes after incubation with
CLCF-1. CLCF-1 increased both JAK2 and STAT3 phosphorylation.
Data from Savin et al. [10]

P；Ｆ＜ activity

0.9
0.8
0.7
0.6
0.5
0.4
0.3
FSGS Serum

JAK2 inhibitor + FSGS Serum

(c) Effect of the specific JAK2 inhibitor BMS91154 on the increase in 𝑃alb
induced by serum of 11 individual patients with FSGS. Glomeruli were
incubated with FSGS serum only or with BMS91154 for 15 minutes prior
to the addition of FSGS patient plasma, 5% vol/vol. Values represent
𝑃alb activity after incubation with FSGS serum only and 𝑃alb activity
after preincubation with inhibitor and then with FSGS sera. In this
experiment, the 𝑃alb activity of FSGS serum was diminished from 0.77
to 0.44 [9] by preincubation of glomeruli with the inhibitor. Bars show
averages and lines depict sera of individual patients. Data from Sharma
et al. [9]

(i)

(ii)

(iii)

(d) Cytoskeleton of immortalized murine podocytes after incubation with CLCF-1 for up to 60 minutes. (i) Prior to incubation,
there were many nearly parallel actin filaments near the base of the cell. Cells had filopodia that extended in several directions and
were tightly adherent to the coverslip on which they were grown. (ii) After 15 minutes of incubation, the number and thickness
of basal actin filaments decreased, filopodia retracted, and the number and extent of lamellipodia increased markedly. (iii) By 60
minutes, nearly all large actin filaments had been lost and the cell had assumed a rounded configuration with extensive formation of
lamellipodia with actin arcs. These confocal micrographs are representative of those obtained in during performance of published
studies [10]

Figure 2
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glomerular dysfunction that arises directly from responses to
a plasma substance and leads to renal failure has been defined.
Targeted therapy may require knowledge of cell signaling
during exposure to plasma of patients with recurrent FSGS
or to the components of such plasma. Human trials will
be required to prove the relevance and efficacy of proposed
therapies.
Cultured immortalized murine and human podocytes
have also been used in functional assays to define plasma
activity. Assay parameters include alterations in the pattern
of actin cytoskeleton [68]. Activation of 𝛽3 integrin, as
evidenced by its phosphorylation, has recently been proposed
as an indicator of podocyte injury and a high throughput
assay presented as a model for discovery of novel therapeutics
[92]. Increased podocyte motility manifest as migration into a
“scratch” defect in a nearly confluent cell layer has also been
used to measure activity [68, 93]. We and others have used
alterations in cytoskeleton configuration as a measure of the
effects of FSGS samples and confirmed that cytoskeleton is
reorganized after incubation in FSGS serum or a candidate
cytokine [10]. Figure 2(d) illustrates cytoskeleton responses
of podocytes during incubation with CLCF-1. During incubation with CLCF-1, filopodia retract and basal parallel actin
filaments are attenuated and decrease in number. Simultaneously, lamellipodia become more prominent, the cells assume
a more rounded state, and short nonparallel actin filaments
and actin arcs predominate [10].

7. Targets for Therapy in FSGS and
Its Recurrence
Trials in FSGS and its posttransplant recurrence have focused
on agents that may remove or neutralize the injurious factors
themselves (PP, IA [28, 94–96], and galactose [55, 97–99]),
modify the immune response by interacting with glucocorticoid and/or melanocortin receptors (prednisone, dexamethasone, and ACTH as Acthar Gel), alter cellular immunity
(calcineurin inhibitors including tacrolimus, cyclosporine A,
humanized antibodies to components of B cells (rituximab),
and T cells (abatacept)), and attempt to limit fibrosis by antibodies to the cytokines TGF𝛽 and TNF𝛼. A number of agents,
including glucocorticoids and calcineurin inhibitors, exert
protective effects on podocytes by changing protein expression profiles [100–103] and stabilizing actin cytoskeleton
[104]. The antiproteinuric effects of angiotensin converting
inhibitors and angiotensin receptor blockers (ARBs) are well
known and appear to occur regardless of the etiology of proteinuria. Results of a randomized controlled trial of a blocker
both of angiotensin and of endothelin receptor have been
reported in abstract form H. Trachtman. Am Soc Nephrol,
Annual Meeting, November, 2016, HI-OR06, and showed
marked reduction of proteinuria in about 28% of FSGS on
sparsentan versus 9% in those treated with irbesartan. Clinical trials related to FSGS are listed in https://ClinicalTrials
.gov and include therapies related to corticosteroids and
ACTH gel, inhibitors of angiotensin and endothelin receptors,
immunosuppressive agents including calcineurin inhibitors
and monoclonal antibodies, extracorporeal interventions
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using PP, IA, and lipopheresis, an inhibitor of sodium/glucose
transporter 2 (SGLT2), and treatment with vitamin D and
retinoids. Results of most of these trials have not yet been
published. Others have shown a positive effect on proteinuria
or disease progression in only a minority of subjects [105].

8. Completed Trials in Patients with FSGS in
Native Kidneys
Large-scale consortia are necessary to the study of orphan
diseases such as FSGS. The Toronto Registry has followed
patients with common glomerular diseases, FSGS, membranous nephropathy, and IgA nephropathy and has generated
a rich experience in regard to natural history and therapy.
Studies established that partial as well as complete remissions
lead to more stable renal function and prolonged renal
survival. Cyclosporine decreases proteinuria in glomerular
disease of several etiologies; CsA-induced nephrotoxicity can
be minimized by use of lower doses. Mycophenolate (MMF)
also induces remission in many patients with FSGS. In a trial
comparing CsA to no CsA in FSGS in native kidneys, CsA
was better in reducing remissions [106]. Serum 𝑃alb activity
measured in our lab was not reduced even during clinical
remission of proteinuria [107]. This suggests that CsA directly
protects glomeruli from the effects of continued presence of
the FSGS permeability factor. Additional studies also showed
clinical benefit from CsA treatment [108, 109]. Results of
studies of isolated glomeruli and podocytes confirm that
CsA protects the permeability barrier from the effects of
FSGS serum by nonimmune mechanisms [57]. Protection
of synaptopodin and of the actin cytoskeleton [104] may be
consequent to inhibition of calcineurin activity.
The NIH-funded FSGS Clinical Trial examined the relative efficacy of 2 accepted therapies in 138 subjects randomly
assigned to CsA or MMF plus dexamethasone. The relevant
outcome was complete or partial remission of proteinuria
within 1 year. The patients were selected from those with
steroid resistant FSGS with relatively well preserved renal
function at the time of recruitment. Each treatment regimen
induced remission in about 30% of patients. About 10%
patients in each treatment group developed renal failure or
died during the 78-week study. MMF plus dexamethasone
had more side effects while CsA transiently decreased GFR.
GFR did not differ between the 2 groups at the end of
the study [110]. The trial was limited by relatively advanced
disease and small number of subjects and the short duration
of therapy.
The Phase 2 FONT (Novel Therapies for Resistant FSGS)
trial compared usual care to oral administration of galactose
or injections of anti-TNF alpha (adalimumab, “Humira”).
As in the prior FSGS trial, patients had steroid resistant FSGS
with GFR ≥ 40 ml/min/1.75 m2 . The study was limited by the
small number of enrolled subjects (21 subjects). No subject in
the usual care arm had remission of proteinuria; 2 patients in
each experimental treatment arm had remission. The effect
of galactose was more prolonged and had higher patient
acceptance than was seen with adalimumab treatment [99,
110]. An additional trial of galactose in glomerular disease
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[105] has been published as have several case reports [97, 98].
The trial was marred by heterogeneity of diagnosis and small
number of subjects [105]. Case reports may have been subject
to positive publication bias.

9. Trials to Prevent or Treat Transplant
Recurrence of FSGS
A single center study of the use of plasmapheresis to prevent
of delay FSGS recurrence after transplant was carried out in
patients judged to be at high risk because of prior recurrence
or rapid course to renal failure. There was an apparent benefit
in preventing recurrence and early transplant loss [111]. The
small size of the study and the lack of a control group limit the
strength of the findings. Therapies used in other small series
have failed to prevent recurrence.

10. Rituximab to Prevent Recurrence of
Proteinuria in Patients Receiving Kidney
Transplant for FSGS
An NIH sponsored single center clinical trial in preventing
recurrence by the use of rituximab is being conducted.
The underlying hypothesis is that rituximab will be protective because of its role in control of activity of podocyte
sphingomyelinase-like phosphodiesterase 3b [79]. Rituximab
partially prevented SMPDL-3b and ASMase downregulation
that was observed in podocytes treated with the sera of
patients with recurrent FSGS. Overexpression of SMPDL-3b
or treatment with rituximab was able to prevent disruption
of the actin cytoskeleton and podocyte apoptosis induced by
patient sera. Subjects have been recruited and randomized
but study results are not available at this time.

11. Individualized Immunoadsorption (IA) for
Posttransplant Therapy
Reversal of recurrence and long-term graft survival has been
reported in 66% of 18 renal transplant recipients with ESRD
due to idiopathic FSGS. This report includes noteworthy
details regarding the time course of recurrence. 66.7% of
patients experienced disease recurrence in a mean time
of 0.75 months after transplantation (KTx), with a mean
proteinuria of 8.9 g/day at the time of recurrence. The
majority of patients were adults (mean age, 30.8 years). Both
cadaveric and living related donors were included. Four of
the patients received therapy with rituximab in addition to
IA. During a mean time of follow-up of 48.3 months, about
60% of patients achieved complete remission, and about 40%
achieved partial remission during average follow-up of over 4
years. At the end of follow-up, 67% had functioning grafts and
were in sustained remission, while 33% progressed to ESRD
because of FSGS recurrence [95]. These results reinforce the
notion that use of current therapies in an individualized
and persistent manner can result in marked improvement in
allograft survival.
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12. Glomerular Disease after Kidney
Transplant and Current and Future
Clinical Trials
Although several agents have been proposed as mediators
of FSGS recurrence after transplantation, none have been
definitively proven as etiologic agents. Most studies regarding
recurrence in this orphan disease have been descriptive. A
study of 1435 adult kidney transplants at the Mayo Clinic
showed that as many as 26% of recipients developed glomerular disease by 10 years. FSGS was the diagnosis in 38% of
these while other diagnoses included IgA nephropathy, membranous nephropathy, and mesangial proliferative glomerulonephritis. The risk of glomerular disease was increased with
younger age, females, and steroid free induction and lower
pretransplant serum albumin. Recurrent FSGS increased the
risk of graft failure (𝑅 = 2.82 𝑝 < 0.0001). Overall glomerular
disease caused 22% of allograft losses. These findings emphasize the important impact of glomerular disease in the overall
success and benefit of renal transplantation [112].
An antibody to CD80, abatacept, has been used to treat
FSGS recurrence and some success was initially reported [113]
but others have failed to confirm this effect [114]. Thus, the
utility of this agent is not clear.
We have recently proposed a trial of the JAK inhibitor
ruxolitinib (Jakifi, Incyte, Corp) (REFOCUS, Rescue FSGS).
The decision to emphasize study patients with recurrent
proteinuria and FSGS in renal allografts is based on the
potential to identify the initial stages of injury at a time when
there is little anatomic distortion and to provide intervention
when the injury is most likely to be reversible. The strategy
of enrolling only patients with recurrence will also minimize
the likelihood of confusion arising from the presence of
mutations of podocyte proteins and of inclusion of renal
disease secondary to hypertension, obesity, or environmental
toxins. The choice of ruxolitinib is based on its relative specificity for JAK1 and JAK2 [115]. As an FDA approved drug,
its pharmacokinetics and toxicity have been well defined in
both preclinical and clinical studies [116, 117]. In addition, it
has been used in thousands of patients with hematological
disorders including myelofibrosis [118] and polycythemia
vera and it is under investigation in other hematological
malignancies and solid tumors. Ruxolitinib and several other
JAK inhibitors block the effects of FSGS sera on pSTAT in
cultured podocytes.
We also plan to propose a formal trial of oral or
intravenous galactose in a sample of FSGS patients that
is sufficiently large to confirm or deny general efficacy in
FSGS after transplantation and/or idiopathic FSGS in native
kidneys. The selection of galactose is based on in vitro studies,
on pharmacological effects of galactose on plasma activity,
and on several case reports in pre- and posttransplant patients
[55, 97–99, 105].
The available data regarding idiopathic FSGS is consistent
with the concepts shown in Figure 3. As illustrated, a
circulating substance, which has not been definitively defined
and is labelled here as “cytokine,” is present in the circulation.
This substance appears to interact with specific receptors on
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Untreated FSGS

High cytokine concentration

Treated FSGS
(1) Decreased cytokine concentration

(2a) Cytokine blocker

Receptor and cytokine interaction
(2b) Receptor blocker
(3) Inhibited signaling
Activated signaling

Disordered actin cytoskeleton

(4) Protected actin cytoskeleton

Figure 3: Scheme showing potential targets for therapy in glomerular injury caused by circulating factor or cytokine. The left panel shows
the milieu that favors podocyte dysfunction and proteinuria. Excess activity of an injurious factor or cytokine permits its interaction with
receptors on podocytes which, in turn, activates signaling via JAK2/STAT3 and other pathways. Actin cytoskeleton becomes disordered and
podocyte architecture and function is altered. The right panel shows some potential treatment goals including the following: (1) decrease factor
synthesis or remove it by plasmapheresis, immunoadsorption or other extracorporeal methods; (2a) administer blocker such as galactose or
(2b) receptor blocker such as antibody to specific component or receptor; (3) inhibit intracellular signaling by JAK or STAT inhibitor or
inhibitor of other essential cell pathways; (4) protect actin cytoskeleton by calcineurin inhibitors such as CsA or by a sphingomyelinase
inhibitor such as rituximab. Identification of multiple targets will permit concurrent use of several modalities that may increase effectiveness
while limiting side effects.

the podocytes, activating intracellular signaling pathways and
leading to alterations in cytoskeleton, adhesion, and motility.
Decreasing its total concentration by inhibiting its synthesis
or increasing catabolism, blocking its activity by antibodies
or inhibitors of receptor-ligand interaction, interrupting
intracellular signaling, or enhancing cell mechanisms that
protect cytoskeleton and adhesion may be developed as therapeutic interventions. Multicenter collaborative studies are
essential since no center will have enough patients to permit
meaningful analysis of treatment effect. Early intervention
will provide an opportunity to arrest the disease in its initial
stages. New therapies offer to dramatically improve the lives
of patients with FSGS in native kidneys and permit successful
renal transplantation in those who have progressed to endstage-renal disease.

FSGS in native kidneys or in recurrence after transplantation
while others have been proposed and await implementation.
Problems that must be overcome include heterogeneity of
patients, short duration of studies, small sample size, and
late initiation of therapy. Careful design and participation
of consortia will be required to attain clinical and statistical
significance.

Abbreviations

13. Summary

8,9 EET:
20 HETE:
ACTH:
CLCF-1:
CNTF:
CNTFR𝛼:
sCNTFR𝛼:

Studies of genes expressed in podocytes and the glomerular
capillary wall point to cytoskeleton, cell junctions, cell attachment, and metabolism as potential targets for intervention.
We and others have demonstrated that FSGS serum or plasma
induces increased glomerular capillary permeability in vitro
and alters cytoskeleton and signaling responses of cultured
podocytes. These responses may be used to screen potential
therapeutic agents prior to or simultaneously with conduct of
clinical trials. A number of trials are ongoing in patients with

CRLF-1:
CsA:
FSGS:
gp130:
IA:
IL-6:
INS:
JAK:
LIFR𝛼:

8,9-Epoxyeicosatrienoic acid
20-Hydroxyeicosatetraeonic acid
Adrenocorticotrophic hormone
Cardiotrophin-like cytokine factor-1
Ciliary Neurotrophic Factor
Ciliary Neurotrophic Factor Receptor 𝛼
Soluble Ciliary Neurotrophic Factor
Receptor 𝛼
Cytokine receptor-like factor-1
Cyclosporine A
Focal segmental glomerulosclerosis
Glycoprotein 130
Immunoadsorption
Interleukin-6
Idiopathic nephrotic syndrome
Janus kinase
Leukemia inhibitory factor receptor 𝛼
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NS:
𝑃alb :
PP:
STAT:
suPAR:
TGF𝛽:
TNF𝛼:
Tyk:
VPF:

BioMed Research International
Nephrotic syndrome
Glomerular albumin permeability,
measured during in vitro studies
Plasmapheresis
Signal transducer and activator of
transcription
Soluble urokinase-type plasminogen
activator receptor
Transforming growth factor-𝛽
Tumor necrosis factor-𝛼
Tyrosine kinase
Vascular permeability factor.
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[36] L. Le Berre, C. Hervé, F. Buzelen, C. Usal, J.-P. Soulillou,
and J. Dantal, “Renal macrophage activation and Th2 polarization precedes the development of nephrotic syndrome in
Buffalo/Mna rats,” Kidney International, vol. 68, no. 5, pp. 2079–
2090, 2005.
[37] L. Le Berre, S. Bruneau, K. Renaudin et al., “Development of
initial idiopathic nephrotic syndrome and post-transplantation
recurrence: Evidence of the same biological entity,” Nephrology
Dialysis Transplantation, vol. 26, no. 5, pp. 1523–1532, 2011.
[38] A. Sellier-Leclerc, A. Duval, S. Riveron et al., “A humanized
mouse model of idiopathic nephrotic syndrome suggests a
pathogenic role for immature cells,” Journal of the American
Society of Nephrology, vol. 18, no. 10, pp. 2732–2739, 2007.
[39] J. Dantal, E. Bigot, W. Bogers et al., “Effect of plasma protein
adsorption on protein excretion in kidney-transplant recipients
with recurrent nephrotic syndrome,” The New England Journal
of Medicine, vol. 330, no. 1, pp. 7–14, 1994.
[40] M. Haas, Y. Godfrin, R. Oberbauer et al., “Plasma immunadsorption treatment in patients with primary focal and segmental
glomerulosclerosis,” Nephrology Dialysis Transplantation, vol.
13, no. 8, pp. 2013–2016, 1998.
[41] M. Delville, T. K. Sigdel, C. Wei et al., “A circulating antibody
panel for pretransplant prediction of FSGS recurrence after
kidney transplantation,” Science Translational Medicine, vol. 6,
no. 256, Article ID 256ra136, 2014.
[42] V. Peev, E. Hahm, and J. Reiser, “Unwinding focal segmental
glomerulosclerosis,” F1000Research, vol. 6, p. 466, 2017.
[43] D. S. Charba, R. C. Wiggins, M. Goyal et al., “Antibodies to
protein tyrosine phosphatase receptor type O (PTPro) increase
glomerular albumin permeability (P𝑎𝑙𝑏 ),” American Journal of
Physiology—Renal Physiology, vol. 297, no. 1, pp. F138–F144,
2009.
[44] K. Suthar, A. V. Vanikar, and H. L. Trivedi, “Renal transplantation in primary focal segmental glomerulosclerosis using a
tolerance induction protocol,” Transplantation Proceedings, vol.
40, no. 4, pp. 1108–1110, 2008.
[45] N. Aggarwal, R. Batwara, E. T. McCarthy, R. Sharma, M.
Sharma, and V. J. Savin, “Serum permeability activity in steroidresistant minimal change nephrotic syndrome is abolished by
treatment of hodgkin disease,” American Journal of Kidney
Diseases, vol. 50, no. 5, pp. 826–829, 2007.
[46] E. T. McCarthy, M. Sharma, R. Sharma, R. J. Falk, and J. C.
Jennette, “Sera from patients with collapsing focal segmental
glomerulosclerosis increase albumin permeability of isolated
glomeruli,” Journal of Laboratory and Clinical Medicine, vol. 143,
no. 4, pp. 225–229, 2004.
[47] H. Trachtman, L. A. Greenbaum, E. T. McCarthy et al.,
“Glomerular permeability activity: Prevalence and prognostic
value in pediatric patients with idiopathic nephrotic syndrome,”
American Journal of Kidney Diseases, vol. 44, no. 4, pp. 604–610,
2004.
[48] V. J. Savin and D. A. Terreros, “Filtration in single isolated
mammalian glomeruli,” Kidney International, vol. 20, no. 2, pp.
188–197, 1981.
[49] F. Fan, C. C. Chen, J. Zhang et al., “Fluorescence dilution
technique for measurement of albumin reflection coefficient
in isolated glomeruli,” American Journal of Physiology - Renal
Physiology, vol. 309, no. 12, pp. F1049–F1059, 2015.

12
[50] G. M. Ghiggeri, M. Artero, M. Carraro et al., “Glomerular
albumin permeability as an in vitro model for characterizing
the mechanism of focal glomerulosclerosis and predicting posttransplant recurrence,” Pediatric Transplantation, vol. 8, no. 4,
pp. 339–343, 2004.
[51] M. A. Saleh, E. I. Boesen, J. S. Pollock, V. J. Savin, and
D. M. Pollock, “Endothelin receptor A-specific stimulation
of glomerular inflammation and injury in a streptozotocininduced rat model of diabetes,” Diabetologia, vol. 54, no. 4, pp.
979–988, 2011.
[52] S. Pudur, T. Srivastava, M. Sharma et al., “Serum glomerular
albumin permeability activity: association with rapid progression to end-stage renal disease in focal segmental glomerulosclerosis,” SpringerPlus, vol. 5, no. 1, article no. 432, 2016.
[53] R. Dall’Amico, G. Ghiggeri, M. Carraro et al., “Prediction and
treatment of recurrent focal segmental glomerulosclerosis after
renal transplantation in children,” American Journal of Kidney
Diseases, vol. 34, no. 6, pp. 1048–1055, 1999.
[54] M. L. Artero, R. Sharma, V. J. Savin, and F. Vincenti, “Plasmapheresis reduces proteinuria and serum capacity to injure
glomeruli in patients with recurrent focal glomerulosclerosis,”
American Journal of Kidney Diseases, vol. 23, no. 4, pp. 574–581,
1994.
[55] V. J. Savin, E. T. McCarthy, R. Sharma, D. Charba, and M.
Sharma, “Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity,” Translational
Research, vol. 151, no. 6, pp. 288–292, 2008.
[56] E. T. McCarthy and M. Sharma, “Indomethacin protects permeability barrier from focal segmental glomerulosclerosis serum,”
Kidney International, vol. 61, no. 2, pp. 534–541, 2002.
[57] R. Sharma, M. Sharma, X. Ge, E. T. Mccarthy, and V. J. Savin,
“Cyclosporine protects glomeruli from FSGS factor via an
increase in glomerular cAMP,” Transplantation, vol. 62, no. 12,
pp. 1916–1920, 1996.
[58] M. Sharma, E. T. McCarthy, V. J. Savin, and E. A. Lianos, “Nitric
oxide preserves the glomerular protein permeability barrier by
antagonizing superoxide,” Kidney International, vol. 68, no. 6,
pp. 2735–2744, 2005.
[59] M. Sharma, J. Z. Li, R. Sharma et al., “Inhibitory effect of
Tripterygium wilfordii multiglycoside on increased glomerular
albumin permeability in vitro,” Nephrology Dialysis Transplantation, vol. 12, no. 10, pp. 2064–2068, 1997.
[60] A. J. Dahly-Vernon, M. Sharma, E. T. McCarthy, V. J. Savin, S. R.
Ledbetter, and R. J. Roman, “Transforming growth factor-𝛽, 20HETE interaction, and glomerular injury in Dahl salt-sensitive
rats,” Hypertension, vol. 45, no. 4, pp. 643–648, 2005.
[61] M. Sharma, E. T. McCarthy, D. S. Reddy et al., “8, 9Epoxyeicosatrienoic acid protects the glomerular filtration
barrier,” Prostaglandins & Other Lipid Mediators, vol. 89, no. (12), pp. 43–51, 2009.
[62] R. Sharma, M. Sharma, E. T. McCarthy, X.-L. Ge, and V. J.
Savin, “Components of normal serum block the focal segmental
glomerulosclerosis factor activity in vitro,” Kidney International,
vol. 58, no. 5, pp. 1973–1979, 2000.
[63] G. Candiano, L. Musante, C. Zennaro et al., “Inhibition
of renal permeability towards albumin: A new function of
apolipoproteins with possible pathogenetic relevance in focal
glomerulosclerosis,” Electrophoresis, vol. 22, no. 9, pp. 1819–1825,
2001.
[64] M. Carraro, C. Zennaro, G. Candiano et al., “Nephrotic
urine prevents increased rat glomerular albumin permeability

BioMed Research International
induced by serum from the same patient with idiopathic
nephrotic syndrome,” Nephrology Dialysis Transplantation, vol.
18, no. 4, pp. 689–693, 2003.
[65] J.-M. Heslan, A. Branellec, J. Laurent, and G. Lagrue, “The vascular permeability factor is a T lymphocyte product,” Nephron,
vol. 42, no. 2, pp. 187-188, 1986.
[66] R. Lennon, A. Singh, G. I. Welsh et al., “Hemopexin induces
nephrin-dependent reorganization of the actin cytoskeleton in
podocytes,” Journal of the American Society of Nephrology, vol.
19, no. 11, pp. 2140–2149, 2008.
[67] C. Wei, H. Trachtman, J. Li et al., “Circulating suPAR in two
cohorts of primary FSGS,” Journal of the American Society of
Nephrology, vol. 23, no. 12, pp. 2051–2059, 2012.
[68] C. Wei, S. El Hindi, J. Li et al., “Circulating urokinase receptor as
a cause of focal segmental glomerulosclerosis,” Nature Medicine,
vol. 17, no. 8, pp. 952–960, 2011.
[69] S. Kunigal, A. Kusch, N. Tkachuk et al., “Monocyte-expressed
urokinase inhibits vascular smooth muscle cell growth by
activating Stat1,” Blood, vol. 102, no. 13, pp. 4377–4383, 2003.
[70] K. C. Vallabhaneni, S. Tkachuk, Y. Kiyan et al., “Urokinase
receptor mediates mobilization, migration, and differentiation
of mesenchymal stem cells,” Cardiovascular Research, vol. 90,
no. 1, pp. 113–121, 2011.
[71] J. M. Spinale, L. H. Mariani, S. Kapoor et al., “A reassessment
of soluble urokinase-type plasminogen activator receptor in
glomerular disease,” Kidney International, vol. 87, no. 3, pp. 564–
574, 2015.
[72] D. Cathelin, S. Placier, and M. Ploug, “Administration of
recombinant soluble urokinase receptor per se is not sufficient
to induce podocyte alterations and proteinuria in mice,” Journal
of the American Society of Nephrology, vol. 25, no. 8, pp. 1662–
1668, 2014.
[73] B. Meijers, R. Poesen, K. Claes et al., “Soluble urokinase receptor
is a biomarker of cardiovascular disease in chronic kidney
disease,” Kidney International, vol. 87, no. 1, pp. 210–216, 2015.
[74] S. S. Hayek, S. Sever, Y. A. Ko et al., “Soluble urokinase
receptor and chronic kidney disease,” The New England Journal
of Medicine, vol. 373, no. 20, pp. 1916–1925, 2015.
[75] C. R. Franco Palacios, J. C. Lieske, H. M. Wadei et al., “Urine
but not serum soluble urokinase receptor (suPAR) may identify
cases of recurrent FSGS in kidney transplant candidates,”
Transplantation, vol. 96, no. 4, pp. 394–399, 2013.
[76] G. Candiano, L. Musante, M. Carraro et al., “Apolipoproteins
prevent glomerular albumin permeability induced in vitro by
serum from patients with focal segmental glomerulosclerosis,”
Journal of the American Society of Nephrology, vol. 12, no. 1, pp.
143–150, 2001.
[77] M. Bruschi, P. Catarsi, G. Candiano et al., “Apolipoprotein e in
idiopathic nephrotic syndrome and focal segmental glomerulosclerosis,” Kidney International, vol. 63, no. 2, pp. 686–695,
2003.
[78] J. Lopez-Hellin, C. Cantarell, L. Jimeno et al., “A form of
apolipoprotein a-I is found specifically in relapses of focal
segmental glomerulosclerosis following transplantation,” The
American Journal of Transplantation, vol. 13, no. 2, pp. 493–500,
2013.
[79] T.-H. Yoo, C. E. Pedigo, J. Guzman et al., “Sphingomyelinaselike phosphodiesterase 3b expression levels determine podocyte
injury phenotypes in glomerular disease,” Journal of the American Society of Nephrology, vol. 26, no. 1, pp. 133–147, 2015.

BioMed Research International
[80] E. T. McCarthy, M. Sharma, and V. J. Savin, “Circulating
permeability factors in idiopathic nephrotic syndrome and focal
segmental glomerulosclerosis,” Clinical Journal of the American
Society of Nephrology, vol. 5, no. 11, pp. 2115–2121, 2010.
[81] Y. Shi, W. Wang, P. A. Yourey et al., “Computational EST
database analysis identifies a novel member of the neuropoietic
cytokine family,” Biochemical and Biophysical Research Communications, vol. 262, no. 1, pp. 132–138, 1999.
[82] G. C. Elson, E. Lelievre, C. Guillet, and etal., “CLF associates
with CLC to form a functional heteromeric ligand for the CNTF
receptor complex,” Nature Neuroscience, vol. 3, no. 9, pp. 867–
872, 2000.
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